佩奥尼佛林通过DR3信号通路在3组先天性淋巴细胞中改善慢性结肠炎
Shaowei Huang1, Xueqian Xie1, Bo Xu1
1School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 510006, China.
Journal of pharmaceutical analysis
|July 19, 2024
概括
佩奥尼佛林通过抑制3组先天性淋巴细胞 (ILC3) 中的死亡受体3 (DR3) 途径来修复性结肠炎中的肠壁. 这种天然化合物可以缓解结肠炎,并独立于自适应性免疫系统,增强粘膜的修复.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其特征是肠粘膜屏障功能受损.
- 第三组先天性淋巴细胞 (ILC) 在维持肠道平衡和粘膜修复方面发挥着至关重要的作用.
- ILC3s中的死亡受体3 (DR3) 信号通路与UC的病变发生有关.
研究的目的:
- 调查Paeonia lactiflora*中的一种化合物 - - 佩奥尼佛洛林 - - 是否能在慢性结肠炎中促进肠道粘膜的修复.
- 阐明佩奥尼佛洛林发挥其治疗作用的机制,特别关注ILC3s中DR3信号的抑制.
主要方法:
- 建立了一种由硫酸 (DSS) 诱导的慢性结肠炎的小鼠模型.
- 小鼠接受了不同剂量的帕欧尼佛林,抗TL1A抗体或IgG的治疗.
- 在结肠中分析了DR3信号通路蛋白和ILC3比例,使用西方斑点和流细胞计.
主要成果:
- 佩奥尼佛林治疗显著缓解了DSS诱导的慢性结肠炎,并恢复了肠道粘膜屏障的完整性.
- 佩奥尼佛洛林抑制了ILC3s和调节的关键细胞因子 (IL-17A,GM-CSF,IL-22) 中的DR3信号通路.
- 培欧尼佛林调节的介质在Caco-2细胞中增强了紧密结的表达,表明直接的屏障修复效应.
结论:
- 佩奥尼佛林通过以依赖于ILC3的方式增强肠道屏障来改善慢性结肠炎.
- 佩奥尼佛洛林的治疗机制包括抑制ILC3s中的DR3信号通路.
- 佩奥尼佛洛林为性结肠炎提供了一个有前途的治疗策略,通过准ILC3-介导的粘膜修复.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K


